| Authors: |
Nevill CR; Gloucestershire Retinal Research Group, Cheltenham General Hospital, Cheltenham, UK., Stratton IM; Gloucestershire Retinal Research Group, Cheltenham General Hospital, Cheltenham, UK., Maruti SS; Boehringer Ingelheim Pharmaceuticals Incorporated, Fremont, CA, USA., Massó-González EL; Boehringer Ingelheim International GmBH, Ingelheim am Rhein, Germany., Sivaprasad S; Moorfields Eye Hospital, London, UK., Bailey C; Bristol Eye Hospital, Bristol, UK., Ehrlich M; Boehringer Ingelheim Pharmaceuticals Incorporated, Fremont, CA, USA., Chong V; Boehringer Ingelheim International GmBH, Ingelheim am Rhein, Germany., Scanlon PH; Gloucestershire Retinal Research Group, Cheltenham General Hospital, Cheltenham, UK. p.scanlon@nhs.net.; Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK. p.scanlon@nhs.net.; University of Gloucestershire, Cheltenham, UK. p.scanlon@nhs.net. |
